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Song-Yan Liao1 and Hung-Fat Tse1,2*Abstract
Heart failure after myocardial infarction is the leading
cause of mortality and morbidity worldwide. Existing
medical and interventional therapies can only reduce
the loss of cardiomyocytes during myocardial infarction
but are unable to replenish the permanent loss of
cardiomyocytes after the insult, which contributes to
progressive pathological left ventricular remodeling and
progressive heart failure. As a result, cell-based therapies
using multipotent (adult) stem cells and pluripotent
stem cells (embryonic stem cells or induced pluripotent
stem cells) have been explored as potential therapeutic
approaches to restore cardiac function in heart failure.
Nevertheless, the optimal cell type with the best
therapeutic efficacy and safety for heart regeneration is
still unknown. In this review, the potential pros and
cons of different types of multipotent (adult) stem cells
and pluripotent stem cells that have been investigated
in preclinical and clinical studies are reviewed, and the
future perspective of stem cell-based therapy for heart
regeneration is discussed.cardial regeneration in mammalian hearts and decline with
age. As a result, transplantation of exogenous stem cellsIntroduction
Heart failure (HF) due to loss of cardiomyocytes caused by
myocardial injuries, especially myocardial infarction (MI), is
the leading cause of mortality and morbidity worldwide [1].
Current pharmacological and interventional therapies can
only reduce the loss of cardiomyocytes during MI but are
unable to replenish the permanent loss of cardiomyocytes
after the initial insult, which contributes to progressive
pathological left ventricular (LV) remodeling. Indeed, a
significant proportion of MI survivors develop progressive
HF despite successful revascularization of the coronary
arteries. While heart transplantation is a curative therapy* Correspondence: hftse@hkucc.hku.hk
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© BioMed Central Ltd.2013for severe HF, this therapy is only feasible in a minority of
HF patients due to limited organ supply. As a result, cell-
based therapies using multipotent stem cells (adult stem
cells) and pluripotent stem cells (embryonic stem cells
(ESCs) or induced pluripotent stem cells (iPSCs)) have been
explored as potential therapeutic approaches for cardiac
regeneration. Nevertheless, the optimal delivery method,
efficiency and safety of these different types of stem cells
for transplantation are still unknown. The objective of this
review is to evaluate the pros and cons of different stem
cell-based therapy approaches for heart regeneration in
pre-clinical and clinical studies.Promises of stem cell therapy for heart regeneration
While multipotent cardiac stem cells (CSCs) exist in mam-
malian heart, they only contribute to very limited numbers
of new cardiomyocytes after birth. Dedifferentiation of the
existing cardiomyocytes rather than cardiogenesis from
endogenous CSCs appears to be the major mechanism of
myocardial repair during aging and after injury [2]. Unfor-
tunately, these mechanisms are rather ineffective for myo-
into the injured heart to enhance cardiogenesis has been in-
vestigated as a therapeutic approach for heart regeneration.
Currently, two major types of stem cells are being investi-
gated: multipotent stem cells (adult stem cells) and pluripo-
tent stem cells (ESCs or iPSCs) have been studied as
potential cell sources for heart regeneration. Adult stem
cells can be isolated from different tissues, such as skeletal
muscle, adipose tissue, peripheral blood or bone marrow
(BM), while ESCs and iPSCs are pluripotent stem cells that
are isolated from blastocysts of human embryos and
derived via reprogramming from somatic cells, respectively
(Figure 1). Pre-clinical and clinical studies showed that
transplantation of these multipotent or pluripotent stem
cells can improve cardiac function in infarcted heart.
Nevertheless, the mechanism by which these stem cells
improve cardiac function after transplantation remains
unclear. While the initial promise is that these transplanted
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Figure 1 Types of adult (multipotent) and pluripotent stem cells for heart regeneration.
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most recent studies have suggested that neither multipotent
[3,4] nor pluripotent stem cells [5,6] can survive long term
and thus do not directly contribute to substantial heart
regeneration. These findings suggest that most of their
beneficial effects on heart function after transplantation are
attributed to various degrees of other indirect actions, in-
cluding paracrine actions [7,8], modulation of extracellular
matrix and apoptosis [9] and mobilization of endogenous
stem cells [10] (Figure 1). Unfortunately, the paracrine
factors secreted or released as well as the relative contribu-
tions of other indirect repair mechanisms that are attrib-
uted to different types of stem cells for the improvement of
cardiac function have yet to be determined. On the other
hand, direct cardiac regeneration using pluripotent stem
cells might still be achievable if some of the major hurdles
related to their preparation, engraftment and survival can
be addressed in the future.
Types of stem cells
Multipotent (adult) stem cells
Different types of adult stem cells that are proven to be
multipotent, including skeletal myoblasts, hematopoietic
stem cells (HSCs), endothelial progenitor cells (EPCs), mes-
enchymal stem cells (MSCs), and CSCs, have been investi-
gated for heart regeneration (Figure 1). These adult stem
cells can be isolated from patients for autologous trans-
plantation without risk of immunological rejection, and
thus are more feasible and readily available for clinical test-
ing. Indeed, these stem cells are currently being investigatedfor treatment of acute MI, chronic myocardial ischemia
and HF (Figure 2).
Skeletal myoblasts
Skeletal myoblasts are skeletal muscle precursor cells that
can be isolated from skeletal muscle biopsies and expanded
ex vivo to quantities sufficient for autologous transplant-
ation [11]. In an animal model of MI, skeletal myoblasts
engrafted into the infarcted myocardium and could be
differentiated into myotubules after transplantation to
improve cardiac function [12]. Unfortunately, subsequent
clinical trials showed that skeletal myoblast transplantation
did not improve cardiac function after HF and may increase
the risk of ventricular tachyarrhythmias. The proarrhythmia
that occurs after skeletal myoblast transplantation may be
attributed to the loss of connexin-43 expression after
in vitro differentiation and results in the failure of electrical
integration with the host myocardium [13]. While these
studies suggest that skeletal myoblasts might not be the
optimal cell type for cardiac regeneration, the insights
obtained from these results have highlighted the important
issue of potential proarrhythmias after stem cell therapy.
Bone marrow-derived cells
Adult BM is a rich source of stem cells - HSCs, EPCs and
MSCs constitute up to approximately 2% of the total BM
cell populations. Similar to skeletal myoblasts, these BM-
derived stem cells can be readily harvested and isolated
based on their expression of surface markers and expanded
ex vivo for autologous transplantation without any immune
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Figure 2 Overview of the types of adult stem cells being investigated for the treatment of acute myocardial infarction, chronic
myocardial ischemia and heart failure.
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through selective sorting for a particular set of surface anti-
gens, including Lin- c-kit+, Sca-1+, CD34, CD38, CD45,
CD133, and KDR [14-16]; MSCs can be isolated and
expanded easily from BM cells due to their ability to adhere
to culture dishes, and can be further characterized by their
expression of CD44, CD54 and CD105 [17,18]. In vitro ex-
periments have shown that these BM-derived stem cells are
able to trans-differentiate into various cell types, including
neurons, hepatocytes, skeletal muscles and cardiomyocytes
under appropriate culture conditions [19,20]. Experimental
studies suggested that transplantation of unselected BM-
derived cells or selected HSCs, EPCs or MSCs into the
acute or chronic ischemic myocardium result in various
degrees of in vivo neo-angiogenesis, and improvement in
cardiac function. As discussed above, indirect actions, such
as paracrine effects, rather than direct cardiac trans-
differentiation of these BM-derived cells, are likely the
major mechanism for the improvement of cardiac function
after transplantation. The encouraging results from pre-
clinical studies with different types of BM-derived cells
(including mononuclear BM cells, HSCs, EPCs and MSCs)
resulted in a series of pilot clinical trials investigating the
potential therapeutic use of these BM-derived cells in
patients with acute MI, chronic myocardial ischemia and
HF (Figure 2). Despite the high degree of heterogeneity in
terms of cell population, dose, preparation and delivery
methods, meta-analysis of these clinical trials [21,22] did
suggest that transplantation of these BM-derived cells is
remarkably safe, has modest effects with regard to reducing
LV dysfunction and remodeling after acute MI, and
improves symptoms in patients with chronic myocardial
ischemia. On the other hand, the clinical efficacy of theseBM-derived stem cells in patients with more severe LV
dysfunction after MI [23] or chronic HF [24] appears to be
less impressive or negative. This is likely attributed to their
poor direct cardiogenic potential to achieve true myocardial
regeneration in the setting of severe LV dysfunction.
Furthermore, the therapeutic effects of BM-derived cells for
autologous transplantation are also limited by the reduction
in their numbers as well as impairment of proliferation and
function associated with ageing and co-morbidities in
patients with cardiovascular diseases [25,26]. Therefore, it
is challenging to yield sufficient functional BM-derived
stem cells via direct isolation or ex-vivo expansion for
transplantation (Figure 3).
Currently, there are very limited data directly comparing
safety and efficacy between these different types of BM-
derived cells for therapeutic use. Nevertheless, emerging
data suggest that more selected populations of these BM-
derived stem cells, such as CD34(+) EPCs or MSCs, rather
than BM mononuclear cells or HSCs, might have better
therapeutic efficacy [27,28].
Endothelial progenitor cells
By definition, EPCs represent a subset of progenitor cells
that circulate in the BM and peripheral blood that have the
ability to differentiate into endothelial cells. EPCs are
mobilized from the BM into the peripheral circulation in
response to stress as well as hematopoietic growth factors
and thus can be collected for therapeutic use with an
apheresis system based on their expression of surface
markers, such as CD34 and CD133 [28]. Although isolation
of EPCs from peripheral blood is less invasive than direct
BM cell harvesting, the number of EPCs obtained is lower,
and is associated with the cost and potential side effects
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Figure 3 Pros and cons of adult (multipotent) stem cells for heart regeneration.
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effects of EPCs might be better than those with non-
selected BM cells, these share a lot of limitations as thera-
peutic agents, such as reduced numbers and functional
capacity of EPCs in patients with cardiovascular diseases,
and a very limited capacity for ex vivo expansion to yield
sufficient numbers for transplantation [25,26].
Mesenchymal stem cells
MSCs are a subset of stem cells from the stroma of BM as
well as other sources, such as adipose tissues, cord blood
and placenta, that are positive for CD44, CD54 and CD105,
but negative for HSC markers CD34 and CD133. In the
BM, they account for only about 0.01% of the BM mono-
nuclear cell fraction. MSCs can be isolated and expanded
easily from BM or other sources due to their ability to
adhere to culture dishes [17,18]. MSCs are denoted by their
ability to differentiate into cells of the mesenchymal lineage.
However, many studies have reported that MSCs also have
pluripotent plasticity and are able to differentiate into
other somatic cell types in vitro, including cardiomyocytes
[29,30]. Indeed, preclinical studies in animal models of
MI have demonstrated that transplanted MSCs have the
potential to differentiate into cardiomyocytes [31], smooth
muscle cells [32] and endothelial cells [33]. Moreover,
experimental studies have shown that MSC transplantation
can induce angiogenesis in ischemic myocardium and im-
proves myocardial function [34,35]. Pilot clinical trials
showed that autologous MSCs could improve cardiac
function in patients with acute MI [36,37] and HF [38].
Furthermore, these cells possess low potential for immune
rejection due to the low level of expression of class II major
histocompatibility complex II antigen and can inhibit theproliferation and function of immune cells, such as T cells,
B cells, natural killer cells and dendritic cells [39,40]. There-
fore, MSCs may be used as a cost-effective ‘off-the-shelf ’
allogeneic cell source for the treatment of MI and HF.
Indeed, recent studies [41] have shown that allogeneic
MSCs are as effective as autologous MSCs for the treat-
ment of acute MI. Therefore, there is a growing interest in
using MSCs as a therapeutic agent for heart regeneration as
they can be more easily obtained from different sources
than other stem cells, expanded ex vivo to yield sufficient
numbers and used in autologous or allogeneic fashion
for transplantation (Figure 2). While their ability to trans-
differentiate into cardiomyocytes seems to be as low as
other BM-derived cells, priming of autologous MSCs to en-
hance their cardiogenic potential using a cocktail of growth
factors is safe and feasible, and can improve functional class
and LV function in patients with ischemic cardiomyopathy
[42]. Whether this approach can enhance true direct regen-
eration of cardiomyocytes via the transplanted modified
MSCs needs further investigation. Furthermore, the relative
therapeutic efficacy of MSCs derived from different sources
for heart regeneration is also unclear. Recent studies sug-
gest that MSCs derived from pluripotent stem cells such as
ESCs [43] or iPSCs [44] are superior to BM-derived MSCs
for tissue repair.
Cardiac stem cells
While the heart has been considered to be a terminally
differentiated organ, different populations of endogenous
CSCs in low numbers have recently been identified in adult
mammalian heart [2]. Different populations of CSCs resid-
ing in the myocardium can be classified based on their phe-
notypes (cardiospheres and cardiac side population cells) or
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Isl1+, and their ability to differentiate into functional cardio-
myocytes in culture [45]. These resident CSCs can be ob-
tained from surgical and endomyocardial biopsy, and
expanded ex vivo for autologous transplantation. In experi-
mental models of MI, transplanted or mobilized resident
CSCs can engraft and acquire cardiac and vascular pheno-
types in infarcted myocardium to improve myocardial per-
fusion and LV function [46,47].
Pilot clinical trials with intracoronary infusion of autolo-
gous cardiospheres [48] and c-kit+ CSCs [49] in patients
with ischemic cardiomyopathy have demonstrated that
transplantation of these CSCs was safe and had potential
beneficial therapeutic effects. While it has been proposed
that these CSCs are more cardiogenic and have potential to
achieve direct heart regeneration (Figure 2), available results
from these pilot clinical trials did not convincingly demon-
strate sufficient heart regeneration due to the modest [48]
or lack [49] of sufficient improvement of LV function after
transplantation. Although cardiac magnetic resonance im-
aging in these studies showed increased viable myocardium
at targeted regions after transplantation, the relative contri-
butions of direct trans-differentiation to cardiomyocytes
versus myocardial repair via indirect mechanisms after
CSC transplantation remain unclear (Figure 1). Similar to
other adult stem cells, the poor engraftment and survival of
CSCs after transplantation remain major issues. Further-
more, the relative therapeutic efficacies of different popula-
tions of CSCs for heart regeneration are also unclear [50].
Future roadmap for adult stem cells
Currently, several types of adult stem cells, including BM-
derived cells, MSCs and CSCs, are being investigated for
the treatment of acute MI, chronic myocardial ischemia
and HF (Figure 2). The relative accessibility and lack of im-
mune rejection of these autologous cells make their transla-
tion from preclinical to clinical studies easy. Overall,
transplantation of these adult stem cells is feasible and
remarkably safe, without evidence of tumor formation or
proarrhythmias, except for skeletal myoblasts. Unfortu-
nately, skeletal myoblasts failed to fulfill the initial promise
of heart regeneration with only modest or no improvement
in LV function and clinical outcomes. Several major on-
going trials (Table 1) will try to address whether the use of
BM mononuclear cells can improve clinical outcome and
reduce mortality in patients with acute MI. The majority of
the trials used autologous BM or MSCs in patients with
acute MI or ischemic cardiomyopathy. Moreover, both
intracoronary and intramyocardial injection of those cells is
being tested. In general, the major shortcomings of these
adult stem cells include limited cardiogenic potential, low
proliferative ability, poor engraftment and survival after
transplantation, and reduced numbers and function in sick
patients with severe cardiovascular diseases (Figure 3). As aresult, alternative cell types, such as MSCs or cardiac stem
cells derived from allogeneic and non-BM sources, such as
adipose tissue and umbilical cord, and modified MSCs or
cardiac stem cells, which have been proposed to have
superior therapeutic efficacy to autologous BM-derived
cells, are also under clinical investigation (Table 1). Cur-
rently, MSCs and CSCs seem to be the most promising
adult multipotent stem cell therapy. Nevertheless, the opti-
mal cell type, methods and timing of delivery and mecha-
nisms of action need to be further investigated. Moreover,
various combinations of these adult stem cells may prove
to be more effective than just a single stem cell type in the
future [51].
Pluripotent stem cells
While adult stem cells have varying cardiogenic trans-
differentiation ability, pluripotent stem cells, such as ESCs
and iPSCs, have unambiguous potential for differentiation
into functional cardiomyocytes. Most important, these
pluripotent stem cells are able to self-renew indefinitely as
an unlimited cell source for tissue regeneration. Under
appropriate culture conditions with selected growth factors,
both ESCs [52] and iPSCs [53] can be differentiated into
cardiomyocytes in vitro. As a result, ESC- or iPSC-derived
cardiomyocytes have been considered to be one of the most
promising cell sources for cardiac regeneration.
Embryonic stem cells
ESCs are pluripotent cells derived from the inner cell mass
of blastocysts of the developing embryo and have the ability
to differentiate into derivatives of the three primary germ
layers: ectoderm, endoderm and mesoderm. As the ‘proto-
type’ of pluripotent stem cells, ESCs are capable of self-
renewal and propagating themselves indefinitely under
defined conditions. Because of their potentially unlimited
capacity for self-renewal, ESC therapies have been proposed
for regenerative medicine and tissue replacement after
injury. Previous studies have shown that transplantation of
murine ESC-derived cardiomyocytes can couple function-
ally with host cardiomyocytes, stimulate formation of new
blood vessels, inhibit apoptosis and improve myocardial
function in an animal model of MI [54,55]. Compared with
BM cells, transplantation of purified ESC-derived cardio-
myocytes was more effective for improving LV function
after MI [56]. Similarly, preclinical studies have demon-
strated that human ESC-derived cardiomyocytes can
survive, proliferate and mature after transplantation to
improve LV function in a mouse model of MI [57,58].
Furthermore, the transplanted human ESC-derived cardio-
myocytes were found to be electromechanically integrated
with host cardiomyocytes and reduced the risk of inducible
cardiac arrhythmia without teratoma formation [59]. How-
ever, the number of engrafted ESC-derived cardiomyocytes
remained small and the functional benefit observed early
Table 1 Ongoing clinical trials on stem cell therapy for treatment of acute myocardial infarction and heart failure (Clinicaltrials.gov)
Trial name
(reference) Cell type Source
Route
of delivery Endpoint
Phase
of trial
Number
of patients Disease status
Study
identifier Trial title
MARVEL/
Warren et al.
Skeletal
myoblasts
Autologous Intramyocardial Safety/
efficacy
Phase I
and II
170 Ischemic
cardiomyopathy
NCT00526253 To Assess Safety and Efficacy of Myoblast Implantation Into
Myocardium Post Myocardial Infarction
MYSTAR-5-YEAR/
Mariann et al.
BM
mononuclear
cells
Autologous Intramyocardial
and
intracoronary
Safety/
efficacy
Phase I
and II
60 Ischemic
cardiomyopathy
NCT01395212 Long-term Follow-up of Patients With Ischemic Heart Disease
Treated With Stem Cell Therapy
COAT/Sandeep et al. BM
mononuclear
cells
Autologous Intracoronary Safety/
efficacy
Phase I
and II
40 Ischemic
cardiomyopathy
NCT01625949 Stem Cell Therapy in Patients With Myocardial Infarction and
Persistent Total Occlusion of Infarct Related Artery
AMIRST/Ashok et al. BM
mononuclear
cells
Autologous Intracoronary Safety/
efficacy
Phase I
and II
30 Acute MI NCT01536106 Rapid Delivery of Autologous Bone Marrow Derived Stem Cells
in Acute Myocardial Infarction Patients
BAMI/Anthony et al. BM
mononuclear
cells
Autologous Intracoronary Safety/
efficacy
Phase III 3,000 Acute MI NCT01569178 The Effect of Intracoronary Reinfusion of Bone Marrow-derived
Mononuclear Cells (BM-MNC) on All Cause Mortality in Acute
Myocardial Infarction
AMR-1/Arshed et al. BM CD34+ Autologous Intracoronary Safety/
efficacy
Phase I
and II
40 Acute MI NCT00313339 Intra-coronary Infusion of Bone Marrow Derived Autologous
CD34+ Selected Cells in Patients With Acute Myocardial Infarction
PreSERVE-AMI/
Arshed et al.
BM CD34+ Autologous Intracoronary Safety/
efficacy
Phase I
and II
160 Ischemic
cardiomyopathy
NCT01495364 AMR-001 Versus Placebo Post ST Segment Elevation Myocardial
Infarction
NOGA-DCM/
Vrtovec et al.
BM CD34+ Autologous Intramyocardial
versus
intracoronary
Safety/
efficacy
Phase I
and II
90 Dilated
cardiomyopathy
NCT01350310 Safety and Efficacy Study of Intramyocardial Stem Cell Therapy
in Patients With Dilated Cardiomyopathy
IMPACT-CABG/
Nicolas et al.
BM CD133+ Autologous Intramyocardial Safety/
efficacy
Phase I
and II
20 Ischemic
cardiomyopathy
NCT01033617 IMPlantation of Autologous CD133+ sTem Cells in Patients
Undergoing CABG
PERFECT/Gustav et al. BM CD133+ Autologous Intramyocardial Efficacy Phase II 142 Ischemic
cardiomyopathy
NCT00950274 Intramyocardial Transplantation of Bone Marrow Stem Cells in
Addition to Coronary Artery Bypass Graft (CABG) Surgery
SELECT-AMI/Jozef et al. BM CD133+ Autologous Intracoronary Safety/
efficacy
Phase I
and II
60 Acute MI NCT00529932 A Trial Using CD133 Enriched Bone Marrow Cells Following
Primary Angioplasty for Acute Myocardial
Infarction
AlsterMACS BM CD133+ Autologous Intramyocardial
versus
intracoronary
Safety/
efficacy
Phase I
and II
64 Ischemic
cardiomyopathy
NCT01337011 Intra-coronary Versus Intramyocardial Application of Enriched
CD133pos Autologous Bone Marrow Derived Stem Cells
ENACT-AMI/
Duncan et al.
Endothelial
progenitor
cells
Autologous Intracoronary Efficacy Phase II 100 Acute MI NCT00936819 Enhanced Angiogenic Cell Therapy - Acute Myocardial
Infarction Trial
REPAIR-ACS/
Andreas et al.
BM derived
progenitor
cells
Autologous Intracoronary Efficacy Phase II 100 Acute MI NCT00711542 Effects of Intracoronary Progenitor Cell Therapy on Coronary
Flow Reserve After Acute MI
ESTIMATION/
Evgeny et al.
BM MSCs Autologous Intramyocardial Efficacy Phase II 50 Acute MI NCT01394432 Study for Endocardial Mesenchymal Stem Cells Implantation in
Patients After Acute Myocardial Infarction
Kastrup et al. BM MSCs Autologous Intramyocardial Efficacy Phase II 60 Ischemic
cardiomyopathy
NCT00644410 Autologous Mesenchymal Stromal Cell Therapy in Heart Failure
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Table 1 Ongoing clinical trials on stem cell therapy for treatment of acute myocardial infarction and heart failure (Clinicaltrials.gov) (Continued)
Maskon et al. BM MSCs Autologous Intracoronary Safety/
efficacy
Phase I
and II
80 Ischemic
cardiomyopathy
NCT01720888 Intracoronary Autologous Mesenchymal Stem Cells Implantation
in Patients With Ischemic Dilated Cardiomyopathy
RELIEF/Yang et al. BM MSCs Autologous Intracoronary Safety/
efficacy
Phase I
and II
135 Acute MI NCT01652209 A Randomized, Open labEled, muLticenter Trial for Safety and
Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells
Acute Myocardial inFarction
MESAMI/ Jerome et al. BM MSCs Autologous Intramyocardial Safety Phase I 10 Ischemic
cardiomyopathy
NCT01076920 Mesenchymal Stem Cells and Myocardial Ischemia
PoseidonDCM/
Joshua et al.
BM MSCs Allogeneic
versus
autologous
Intramyocardial Safety/
efficacy
Phase I
and II
36 Dilated
cardiomyopathy
NCT01392625 PercutaneOus StEm Cell Injection Delivery Effects On
Neomyogenesis in Dilated CardioMyopathy
Perin et al. Mesenchymal
precursor cells
Allogeneic Intramyocardial Safety/
efficacy
Phase I
and II
25 Ischemic
cardiomyopathy
NCT00555828 Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs)
in Subjects With Recent Acute Myocardial Infarction
AMICI/ Eric et al. Mesenchymal
precursor cells
Allogeneic Intracoronary Safety/
efficacy
Phase I
and II
225 Acute MI NCT01781390 Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion
in MyoCardial Infarction
MyStromalCell/
Kastrup et al.
Adipose MSCs Autologous Intramyocardial Efficacy Phase II 60 Ischemic
cardiomyopathy
NCT01449032 MesenchYmal STROMAL CELL Therapy in Patients With Chronic
Myocardial Ischemia
ATHENA/Perin et al. Adipose MSCs Autologous Intramyocardial Safety/
efficacy
Phase I
and II
45 Ischemic
cardiomyopathy
NCT01556022 Safety and Feasibility Trial of Adipose-Derived Regenerative Cells
in the Treatment of Chronic Myocardial Ischemia
PRECISE/
Fernández-Avilés et al.
Adipose MSCs Autologous Intramyocardial Safety/
efficacy
Phase I
and II
36 Ischemic
cardiomyopathy
NCT00426868 A Randomized Clinical Trial of adiPose-deRived stEm and
Regenerative Cells In the Treatment of Patients With Non
revaScularizable ischEmic Myocardium
APOLLO/
Serruys et al.
Adipose MSCs Autologous Intramyocardial Safety/
efficacy
Phase I
and II
48 Acute MI NCT00442806 A Randomized Clinical Trial of AdiPOse-derived Stem ceLLs in
the Treatment of Patients With ST-elevation myOcardial
Infarction
RIMECARD Umbilical cord
MSCs
Allogeneic Intravenous Safety/
efficacy
Phase I
and II
30 Ischemic
cardiomyopathy
NCT01739777 Randomized Clinical Trial of Intravenous Infusion Umbilical Cord
Mesenchymal Stem Cells on Cardiopathy
CHART-1/Terzic et al. BM MSC
cardiopoietic
cells
Autologous Intramyocardial Safety/
efficacy
Phase I
and II
240 Ischemic
cardiomyopathy
NCT01768702 Safety and Efficacy of Autologous Cardiopoietic Cells for
Treatment of Ischemic Heart Failure
RECONSTRUCT/
Marban et al.
Cardiosphere-
derived cells
Autologous Intramyocardial Safety/
efficacy
Phase I
and II
24 Ischemic
cardiomyopathy
NCT01496209 REgenerative CardiOsphere iNjection to STRengthen
dysfUnCTional Hearts
ALLSTAR/Smith et al. Cardiosphere-
derived cells
Allogeneic Intracoronary Safety/
efficacy
Phase I
and II
274 Ischemic
cardiomyopathy
NCT01458405 Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Gourabi et al. Cardiac stem
cells
Autologous Intracoronary Safety/
efficacy
Phase I
and II
50 Ischemic
cardiomyopathy
NCT01758406 Transplantation of Autologous Cardiac Stem Cells in
Ischemic Heart Failure
MESS/Mariann et al. Cardiac stem
cells
Autologous Intracoronary Safety/
efficacy
Phase III 1,000 Ischemic
cardiomyopathy
NCT01098591 Meta-analysis of Cardiac Stem Cell Studies
BM, bone marrow; MI, myocardial infarction; MSC, mesenchymal stem cell.
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cytes was not sustained over long-term follow-up [58,60].
Nevertheless, there are several major concerns related to
the clinical application of human ESC-based therapies.
First, there are relevant ethical and regulatory issues that
need to be addressed. Second, despite the lack of teratoma
formation in animals, the potential risk of tumorigenicity
after transplanting a large number of human ESC-derived
cardiomyocytes remains unclear. It is a major challenge to
produce clinical grade, high purity ESC-derived cardiomyo-
cytes as transplanting undifferentiated ESCs carries the risk
of teratoma formation [61]. Third, as ESC-derived cardio-
myocytes are allogeneic cells, long-term immunosuppres-
sion will be required. Moreover, the long-term survival rate
of these isolated transplanted cellular grafts, even with the
use of immunosuppression, is unknown. Fourth, the
heterogeneous phenotypes and maturity of ESC-derived
cardiomyocytes can be problematic. Compared with adult
mature cardiomyocytes, ESC-derived cardiomyocytes com-
prise a mixed cell population, such as nodal, atrial and
ventricular phenotypes [52], as well as immature electro-
physiological properties, including lengthened action dur-
ation and depolarized resting membrane potential [5,52].
Transplantation of these mixed populations of immature
cardiomyocytes with spontaneous electrical activity might
induce cardiac arrhythmias early after transplantation
before they are fully matured and integrated in vivo with
host cardiomyocytes [62,63].
Induced pluripotent stem cells
Recent breakthroughs in the generation of pluripotent
iPSCs via ‘forced’ expression of specific genes (Oct3/4,
Sox2, Klf4, c-Myc or Oct3/4, Sox2, Nanog, Lin28) in som-
atic cells [64,65] might overcome some of the limitations of
human ESCs for heart regeneration. As iPSCs are generated
from human somatic cells there are no ethical dilemmas as
with human ESCs, and they can theoretically provide
autologous cells for transplantation without the need for
immunosuppression. Similar to ESCs, iPSCs are pluripotent
stem cells that can be differentiated into cell types from all
three germ layers in vitro. Indeed, iPSCs can also be differ-
entiated into functional cardiomyocytes and have similar
therapeutic efficacy as ESC-derived cardiomyocytes for
heart regeneration. After transplantation into the animal
model of MI, iPSC-derived cardiomyocytes were able to
survive and integrate with host myocardium to improve LV
function and attenuate LV dilatation [66,67]. However,
iPSCs appear to be more tumorigenic than ESCs and
produced massive teratomas after transplantation into
immune-deficient hosts [68,69]. Similar to ESCs, the ability
to differentiate and purify these iPSC-derived cardiomyo-
cytes to reduce the risk of teratoma formation is critical for
future development of iPSC-based therapy. Moreover, the
use of viral vectors in the reprogramming procedure mayresult in mutagenesis or malignant transformation. As a
result, it is important to optimize other methods for repro-
gramming, such as gene delivery via non-integrating
viruses, plasmid DNA or recombinant DNA, before clinic
applications [70,71].
Future roadmap for pluripotent stem cells
As discussed above, only ESCs or iPSCs are pluripotent
stem cells that possess the ability to produce sufficient
amounts of functional cardiomyocytes on a large scale for
‘true’ heart regeneration (Figure 4). On the other hand, the
risks of using ESC- or iPSC-derived cardiomyocytes in the
clinic are much higher than with adult stem cells due to the
potential risk of tumorigenicity and proarrhythmias. Several
main hurdles need to be addressed before their clinical
application. First, further development of differentiation
protocols to yield high purity (100%) functional cardio-
myocytes at large scales (tens to hundreds of billions) with-
out the need for any genetic modification for sorting is
needed. Second, future studies are needed to determine the
optimal degree of maturation of ESC- or iPSC-derived
cardiomyocytes for transplantation. While heterogeneous
and immature electrical phenotypes of these cells might
contribute to proarrhythmias, fully mature cardiomyocytes
have poor survival and engraftment after transplantation
[72]. Third, the substantial cost associated with generation
of clinical grade ESC or iPSC lines, as well as their differen-
tiation and purification under good clinical practice at large
scales, will limit their feasibility as cell sources for heart
regeneration in the majority of patients. Fourth, future
strategies are needed to address the issue of poor engraft-
ment and survival of these cells after transplantation, as
with adult stem cells. Finally, other than the potential appli-
cation of iPSCs for cardiac regeneration, they have been
proposed as an in vitro platform for specific drug screening
and testing.
The preliminary characterization of iPSC-derived cardio-
myocytes and their validation with over 40 drugs of known
activity suggests that these cells could serve as a new tool
to develop pharmacologically relevant in vitro screens to
detect cardiotoxicity while improving patient safety and
reducing the economic burden of drug attrition [73,74].
New strategies to improve stem cell survival and
engraftment
As discussed above, the major roadblocks for the clinical
application of both adult stem cells and pluripotent stem
cells are significant cell death and apoptosis, lack of cell
engraftment, and poor differentiation after transplant-
ation. Prior studies have shown that only less than 10%
of the BM cells were detected in the infarcted myocar-
dium within 2 hours after injection [75,76]. Similarly,
only a very small proportion of ESC-derived cardiomyo-
cytes could be observed in the infarcted myocardium
Cons
Pros
Transplantation
Electrical instability
Phenotype heterogeneity
Continue proliferation and 
differentiation
Tumor risk 
Proarrhythmia
Pluripotent stem cells
High cardiogenic potential 
Unlimited proliferative 
potential
Functional cardiomyocytes
Cardiac regeneration   
Efficacy
Unlimited supply 
Figure 4 Pros and cons of pluripotent stem cells for heart regeneration.
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heart, both adult cardiomyocytes and the surrounding
extracellular matrix, which provides support to the
cardiomyocytes, are destroyed. Therefore, it is likely that
the inflammatory milieu of the ischemic environment
and the lack of extracellular matrix may be the major
reason for cell death after transplantation. Currently, a
number of different strategies have been proposed to
enhance cell survival and engraftment by ischemic
preconditioning and transgenic overexpression of anti-
apoptotic factors (for example, stromal derived factor-1α
and insulin-like growth factor-1) [77,78] and pro-
survival and pro-angiogenic factors (for example, Akt
and vascular endothelial growth factor) [79,80].
Another approach is via cardiac tissue engineering by
combining scaffold materials and cells to optimize cell
survival and engraftment [81,82]. It is likely that these
transplanted cells will require a supportive biochemical,
physical, and spatial environment for optimal survival that
allows them to differentiate and integrate with the infarcted
myocardium. Common cardiac tissue engineering strategies
include an engineered ‘vehicle’ that facilitates cell growth
and proliferation. This may be a scaffold, a patch or cell
sheet made of either natural or synthetic polymeric mate-
rials similar to the native extracellular matrix, such as
gelatin, collagen, fibrin, Matrigel, alginate and poly (lactic-
co-glycolic acid). Moreover, these ‘vehicles’ also provide
mechanical support to ventricular chamber integrity in
order to limit ventricular wall dilatation, and thus provide
a favorable environment for the transplanted cells to en-
hance cell survival, proliferation and differentiation. The
ideal materials should also be biodegradable and non-
immunogenic.In general, cardiac tissue engineering can be achieved
via either in vitro or in vivo approaches. In the in vitro
approach, cardiac tissue engineering consists of in vitro
generation of a cellular patch by seeding cells on scaf-
folds or patches that are then attached on the epicardial
surface of the myocardium. The advantage of in vitro
cardiac tissue engineering is the possibility of controlling
the shape and size of the constructs and improving
viability of the seeded cells. The main limitation of this
approach is that implantation of these materials involves
an invasive open-chest procedure and the implanted
patches may affect the electrical and mechanical proper-
ties of the host myocardium if they fail to integrate. For
in vivo cardiac tissue engineering, a mixture of biomate-
rials and transplanted cells is injected into the damaged
myocardium. The advantage of this approach is that it is
minimally invasive without the need for major surgery.
On the other hand, the growth and differentiation of
the transplanted cells in the biomaterial cannot be con-
trolled or optimized before transplantation. Neverthe-
less, both in vitro and in vivo cardiac tissue engineering
using BM stem cells [83], CSCs [84] and ESC-derived
cardiomyocytes [85] have been shown to increase
cell engraftment, enhance angiogenesis and improve LV
function after transplantation.
Future perspectives of stem cell therapy for heart
regeneration
Stem cell therapy is a promising therapeutic approach for
the treatment of HF. It is still at an early stage of develop-
ment, however, and many issues remain to be addressed.
Preclinical studies and pilot clinical trials have revealed
many limitations of current stem cell therapies based
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and apoptosis, lack of cell engraftment, and limited heart
regeneration after cell transplantation. Both adult and pluri-
potent stem cells have their own advantages and disadvan-
tages as cell sources for heart regeneration. Although no
major safety concerns were raised during initial clinical tri-
als using autologous adult stem cells, potential adverse side
effects, such as the risk of proarrhythmia and tumor forma-
tion, need to be carefully monitored if we intend to use
allogeneic and pluripotent stem cells in the future.
Furthermore, strategies that improve therapeutic efficacy as
well as cellular survival and engraftment, such as modified
stem cells, mixed stem cells and cardiac tissue engineering,
are under development. Finally, techniques that can induce
trans-differentiation of somatic cells directly into functional
cardiomyocytes in vitro and in vivo have also been devel-
oped recently, and may be proven to be a more effective
strategy for promoting endogenous heart regeneration
rather than transplanting exogenous stem cells in the
future [86].Note: This article is part of a thematic series on Cardiovascular
regeneration edited by Ronald Li. Other articles in the series can
be found online at http://stemcellres.com/series/cardiovascular.Abbreviations
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